BioCentury | Jun 7, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Mouse studies suggest miR-31 inhibitors could help treat chronic lymphocytic choriomeningitis virus (LCMV) infection. In a mouse model of chronic LCMV infection, T cell-specific knockout of miR-31 decreased disease scores and serum...
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

Cardiovascular disease INDICATION: Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31 levels were higher in atrial myocytes from AF patients and in the left ventricle of a...
BioCentury | Jan 27, 2014
Company News

IntegraGen, University of Southampton deal

...from colorectal cancer. IntegraGen is planning to use the data to validate the cancer biomarker hsa-miR-31-3p...
BioCentury | Oct 21, 2013
Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

...rights from the hospital, institutes and university for IP covering use of the oncology biomarker hsa-miR-31-3p...
BioCentury | Mar 4, 2013
Company News

IntegraGen, Lab21 deal

...SPARQ PCR technology to develop the assay to detect expression levels of the miRNA biomarker hsa-miR-31-3p...
...disclose financial details. Lab21 said the companies "will explore other opportunities for partnerships" relating to hsa-miR-31-3p...
Items per page:
1 - 5 of 5